Pemetrexed acts as a PPAR γ partial agonist via a unique binding mode that avoids AF-2 engagement, providing a structural basis for designing novel dual-pathway inhibitors for NSCLC therapy.
No takes yet. Share an insight, caveat, or question.
She et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: